Characterization of a serum protein pattern from NSCLC patients treated with Gefitinib

V. M. Garrisi, I. Bongarzone, A. Mangia, M. Cremona, M. De Bortoli, E. Vaghi, D. Galetta, U. Pastorino, M. Quaranta, I. Abbate, A. Paradiso

Research output: Contribution to journalArticle

Abstract

Objectives: The purpose of this study was to evaluate the efficacy of a protein-based pattern in serum previously determined by MALDI-TOF-MS (Matrix Assisted Laser Desorption Ionization-Time of Flight) and considered potentially useful for prediction of clinical outcome of EGFR (epidermal growth factor receptor) TKIs (tyrosine kinase inhibitors) treated patients. Design and methods: We generated SELDI-TOF (Surface Enhanced Laser Desorption Ionization-Time of Flight) spectra in sera of 11 advanced NSCLC treated with Gefitinib. We detected the clusters with m/. z 5843, 11. 445, 11. 529, 11. 685, 11. 759 and 11. 903 which were previously reported to be potential predictors of response to Gefitinib treatment. Results: Four cluster peaks with m/. z 5843, 11. 445, 11. 529, 11. 685 corresponded to SAA (serum amyloid A) protein on the basis on their calculated molecular weight, peptide fingerprinting and antibodies recognition. Conclusions: We confirm that several proteins already reported were isoforms of SAA but further studies are in development in order to evaluate the predictive value of such algorithm.

Original languageEnglish
Pages (from-to)936-940
Number of pages5
JournalClinical Biochemistry
Volume44
Issue number10-11
DOIs
Publication statusPublished - Jul 2011

Keywords

  • Biomarkers
  • NSCLC
  • Proteomics
  • SAA
  • SELDI-TOF

ASJC Scopus subject areas

  • Clinical Biochemistry

Fingerprint Dive into the research topics of 'Characterization of a serum protein pattern from NSCLC patients treated with Gefitinib'. Together they form a unique fingerprint.

  • Cite this